MHC Story
MHCombiotic Inc. (MHC), based in Calgary, Canada, is dedicated to combating antimicrobial resistance (AMR). Founded by Dr. Ali Pormohammad (DVM, MSc, PhD | Medical Microbiology), Professor R J Turner, and CCrest Laboratory. The company was born out of Ali’s postdoctoral research under Professor R J Turner supervision at the University of Calgary. During this research, MHC established collaborations with prestigious institutions such as Harvard University, University of Barcelona, and several research groups across Canada and the U.S. Over three years, the team screened more than 18,000 novel formulations to develop our flagship product, “Combiotic™.”
To validate this technology, independent third-party FDA and Health Canada-approved GMP and GLP labs conducted rigorous safety and efficacy tests. This extensive research led to numerous publications, breakthrough discoveries, and the filing of U.S. and international patents, laying the foundation for MHC. We have received numerous awards, including the 2021 Innovation Postdoc, 2022 Excellence Award Postdoc, 2022 Top 40 under 40, and the 2024 Life Science Fellowship for pioneering innovative technology.
For over a decade, Dr. Pormohammad has been dedicated to AMR research, supported by Professor Turner, MHC’s Chief Scientific Officer, whose expertise spans more than 25 years. With the unwavering support of CCrest Laboratory, a publicly traded pharmaceutical company in Montreal, as a co-funder and early-stage investor.
Through collaboration, innovation, and determination, MHC is driving forward with life-saving products and leading the charge in the fight against AMR. Their journey is a testament to the power of science and teamwork in solving some of the world’s most urgent health challenges.
